Advanced search
Publication Cover
Expert Review of Clinical Immunology Volume 9, 2013 - Issue 12
Submit an article Journal homepage
140
Views
2
CrossRef citations to date
0
Altmetric
Reviews

Optimizing the use of regulatory T cells in allotransplantation: recent advances and future perspectives

Caitlin E BaumDepartment of Medical Microbiology and Immunology, University of Toledo, College of Medicine and Life Sciences, 3000 Arlington Avenue, HEB 263A, Toledo, OH 43614, USACorrespondence[email protected] [email protected]
,
Beata MierzejewskaDepartment of Medical Microbiology and Immunology, University of Toledo, College of Medicine and Life Sciences, 3000 Arlington Avenue, HEB 263A, Toledo, OH 43614, USA
,
Paul M SchroderDepartment of Medical Microbiology and Immunology, University of Toledo, College of Medicine and Life Sciences, 3000 Arlington Avenue, HEB 263A, Toledo, OH 43614, USA
,
Mithun KhattarDepartment of Medical Microbiology and Immunology, University of Toledo, College of Medicine and Life Sciences, 3000 Arlington Avenue, HEB 263A, Toledo, OH 43614, USACorrespondence[email protected] [email protected]
&
Stanislaw StepkowskiDepartment of Medical Microbiology and Immunology, University of Toledo, College of Medicine and Life Sciences, 3000 Arlington Avenue, HEB 263A, Toledo, OH 43614, USACorrespondence[email protected] [email protected]
Pages 1303-1314 | Published online: 10 Jan 2014

References

  • Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155(3), 1151–1164 (1995).
  • Abbas AK, Benoist C, Bluestone JA et al. Regulatory T cells: recommendations to simplify the nomenclature. Nat. Immunol. 14(4), 307–308 (2013).
  • Burchill MA, Yang J, Vang KB et al. Linked T cell receptor and cytokine signaling govern the development of the regulatory T cell repertoire. Immunity 28(1), 112–121 (2008).
  • Goldstein JD, Perol L, Zaragoza B, Baeyens A, Marodon G, Piaggio E. Role of cytokines in thymus- versus peripherally derived-regulatory T cell differentiation and function. Front. Immunol. 4, 155 (2013).
  • Lio CW, Hsieh CS. A two-step process for thymic regulatory T cell development. Immunity 28(1), 100–111 (2008).
  • Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat. Rev. Immunol. 3(3), 253–257 (2003).
  • Kretschmer K, Heng TS, Von Boehmer H. De novo production of antigen-specific suppressor cells in vivo. Nat. Protoc. 1(2), 653–661 (2006).
  • Daniel C, Ploegh H, Von Boehmer H. Antigen-specific induction of regulatory T cells in vivo and in vitro. Methods Mol. Biol. 707, 173–185 (2011).
  • Curotto De Lafaille MA, Lafaille JJ. Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? Immunity 30(5), 626–635 (2009).
  • Lin X, Chen M, Liu Y et al. Advances in distinguishing natural from induced Foxp3(+) regulatory T cells. Int. J. Clin. Exp. Pathol. 6(2), 116–123 (2013).
  • Liang S, Alard P, Zhao Y, Parnell S, Clark SL, Kosiewicz MM. Conversion of CD4+ CD25- cells into CD4+ CD25+ regulatory T cells in vivo requires B7 costimulation, but not the thymus. J. Exp. Med. 201(1), 127–137 (2005).
  • Hall BM, Pearce NW, Gurley KE, Dorsch SE. Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. III. Further characterization of the CD4+ suppressor cell and its mechanisms of action. J. Exp. Med. 171(1), 141–157 (1990).
  • Malek TR, Castro I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity 33(2), 153–165 (2010).
  • Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol. 6(4), 345–352 (2005).
  • Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 4(4), 330–336 (2003).
  • Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 299(5609), 1057–1061 (2003).
  • Khattri R, Cox T, Yasayko SA, Ramsdell F. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat. Immunol. 4(4), 337–342 (2003).
  • Morgan ME, Van Bilsen JH, Bakker AM et al. Expression of FOXP3 mRNA is not confined to CD4+CD25+ T regulatory cells in humans. Hum. Immunol. 66(1), 13–20 (2005).
  • Bennett CL, Christie J, Ramsdell F et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet. 27(1), 20–21 (2001).
  • Gavin MA, Torgerson TR, Houston E et al. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc. Natl Acad. Sci. USA 103(17), 6659–6664 (2006).
  • Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat. Immunol. 3(2), 135–142 (2002).
  • Gotsman I, Grabie N, Gupta R et al. Impaired regulatory T-cell response and enhanced atherosclerosis in the absence of inducible costimulatory molecule. Circulation 114(19), 2047–2055 (2006).
  • Liu W, Putnam AL, Xu-Yu Z et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J. Exp. Med. 203(7), 1701–1711 (2006).
  • Zheng Y, Rudensky AY. Foxp3 in control of the regulatory T cell lineage. Nat. Immunol. 8(5), 457–462 (2007).
  • Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu. Rev. Immunol. 30, 531–564 (2012).
  • Shevach EM. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 30(5), 636–645 (2009).
  • Takahashi T, Tagami T, Yamazaki S et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. 192(2), 303–310 (2000).
  • Sugimoto N, Oida T, Hirota K et al. Foxp3-dependent and -independent molecules specific for CD25+CD4+ natural regulatory T cells revealed by DNA microarray analysis. Int. Immunol. 18(8), 1197–1209 (2006).
  • Yadav M, Louvet C, Davini D et al. Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. J. Exp. Med. 209(10), 1713–1722, S1711_S1719 (2012).
  • Getnet D, Grosso JF, Goldberg MV et al. A role for the transcription factor Helios in human CD4(+)CD25(+) regulatory T cells. Mol. Immunol. 47(7–8), 1595–1600 (2010).
  • Milpied P, Renand A, Bruneau J et al. Neuropilin-1 is not a marker of human Foxp3+ Treg. Eur. J. Immunol. 39(6), 1466–1471 (2009).
  • Tran DQ, Ramsey H, Shevach EM. Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. Blood 110(8), 2983–2990 (2007).
  • Lal G, Zhang N, Van Der Touw W et al. Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. J. Immunol. 182(1), 259–273 (2009).
  • Murai M, Krause P, Cheroutre H, Kronenberg M. Regulatory T-cell stability and plasticity in mucosal and systemic immune systems. Mucosal Immunol. 3(5), 443–449 (2010).
  • Goodman WA, Cooper KD, Mccormick TS. Regulation generation: the suppressive functions of human regulatory T cells. Crit. Rev. Immunol. 32(1), 65–79 (2012).
  • Takahashi T, Kuniyasu Y, Toda M et al. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int. Immunol. 10(12), 1969–1980 (1998).
  • Thornton AM, Shevach EM. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 188(2), 287–296 (1998).
  • Wing K, Onishi Y, Prieto-Martin P et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 322(5899), 271–275 (2008).
  • Onishi Y, Fehervari Z, Yamaguchi T, Sakaguchi S. Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc. Natl Acad. Sci. USA 105(29), 10113–10118 (2008).
  • Liang B, Workman C, Lee J et al. Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. J. Immunol. 180(9), 5916–5926 (2008).
  • Grossman WJ, Verbsky JW, Barchet W, Colonna M, Atkinson JP, Ley TJ. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 21(4), 589–601 (2004).
  • Grossman WJ, Verbsky JW, Tollefsen BL, Kemper C, Atkinson JP, Ley TJ. Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. Blood 104(9), 2840–2848 (2004).
  • Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ. CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat. Immunol. 8(12), 1353–1362 (2007).
  • Wang G, Khattar M, Guo Z et al. IL-2-deprivation and TGF-B are two non-redundant suppressor mechanisms of CD4+CD25+ regulatory T cell which jointly restrain CD4+CD25- cell activation. Immunol. Lett. 132(1–2), 61–68 (2010).
  • Chen W, Jin W, Hardegen N et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J. Exp. Med. 198(12), 1875–1886 (2003).
  • Collison LW, Workman CJ, Kuo TT et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450(7169), 566–569 (2007).
  • Yamaguchi T, Wing JB, Sakaguchi S. Two modes of immune suppression by Foxp3(+) regulatory T cells under inflammatory or non-inflammatory conditions. Semin. Immunol. 23(6), 424–430 (2011).
  • Cohen JL, Trenado A, Vasey D, Klatzmann D, Salomon BL. CD4(+)CD25(+) immunoregulatory T Cells: new therapeutics for graft-versus-host disease. J. Exp. Med. 196(3), 401–406 (2002).
  • Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 99(10), 3493–3499 (2002).
  • Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J. Exp. Med. 196(3), 389–399 (2002).
  • Trenado A, Sudres M, Tang Q et al. Ex vivo-expanded CD4+CD25+ immunoregulatory T cells prevent graft-versus-host-disease by inhibiting activation/differentiation of pathogenic T cells. J. Immunol. 176(2), 1266–1273 (2006).
  • Hanash AM, Levy RB. Donor CD4+CD25+ T cells promote engraftment and tolerance following MHC-mismatched hematopoietic cell transplantation. Blood 105(4), 1828–1836 (2005).
  • Clark FJ, Gregg R, Piper K et al. Chronic graft-versus-host disease is associated with increased numbers of peripheral blood CD4+CD25high regulatory T cells. Blood 103(6), 2410–2416 (2004).
  • Meignin V, Peffault De Latour R, Zuber J et al. Numbers of Foxp3-expressing CD4+CD25high T cells do not correlate with the establishment of long-term tolerance after allogeneic stem cell transplantation. Exp. Hematol.y 33(8), 894–900 (2005).
  • Rieger K, Loddenkemper C, Maul J et al. Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GvHD. Blood 107(4), 1717–1723 (2006).
  • Trzonkowski P, Bieniaszewska M, Juscinska J et al. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells. Clin. Immunol. 133(1), 22–26 (2009).
  • Brunstein CG, Miller JS, Cao Q et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 117(3), 1061–1070 (2011).
  • Edinger M, Hoffmann P. Regulatory T cells in stem cell transplantation: strategies and first clinical experiences. Curr. opin. Immunol. 23(5), 679–684 (2011).
  • Di Ianni M, Falzetti F, Carotti A et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 117(14), 3921–3928 (2011).
  • Yadav M, Szot G, Russ H et al. Regulatory T cells in prevention of islet-graft rejection in humanized mice (P2230). Presented at: Immunology 2013. Honolulu, HI, USA, 3–7 May 2013.
  • Shalev I, Selzner N, Shyu W, Grant D, Levy G. Role of regulatory T cells in the promotion of transplant tolerance. Liver Transpl. 18(7), 761-770 (2012).
  • Khattar M, Deng R, Kahan BD et al. Novel Sphingosine-1-Phosphate Receptor Modulator KRP203 Combined With Locally Delivered Regulatory T Cells Induces Permanent Acceptance of Pancreatic Islet Allografts. Transplantation 95(7), 919–927 (2013).
  • Miyahara Y, Khattar M, Schroder PM et al. Anti-TCRB mAb Induces Long-Term Allograft Survival by Reducing Antigen-Reactive T Cells and Sparing Regulatory T Cells. Am. J. Transplant. 12(6), 1409–1418 (2012).
  • Guo X, Jie Y, Ren D et al. In vitro-expanded CD4(+)CD25(high)Foxp3(+) regulatory T cells controls corneal allograft rejection. Hum. Immunol. 73(11), 1061–1067 (2012).
  • Shi Q, Lees JR, Scott DW, Farber DL, Bartlett ST. Endogenous expansion of regulatory T cells leads to long-term islet graft survival in diabetic NOD mice. Am. J. Transplant. 12(5), 1124–1132 (2012).
  • Berglund D, Karlsson M, Biglarnia AR et al. Obtaining regulatory T cells from uraemic patients awaiting kidney transplantation for use in clinical trials. Clin. exp. Immunol. 173(2), 310–322 (2013).
  • Baecher-Allan C. Human CD25high Tregs: isolation by beads versus by FACS sorting. Clin. Immunol. 120(2), 234–235 (2006).
  • Haase D, Starke M, Puan KJ, Lai TS, Rotzschke O. Immune modulation of inflammatory conditions: regulatory T cells for treatment of GvHD. Immunol. Res. 53(1–3), 200–212 (2012).
  • Kleinewietfeld M, Starke M, Di Mitri D et al. CD49d provides access to "untouched" human Foxp3+ Treg free of contaminating effector cells. Blood 113(4), 827–836 (2009).
  • Riley JL, June CH, Blazar BR. Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity 30(5), 656–665 (2009).
  • Zheng SG, Wang J, Horwitz DA. Cutting edge: Foxp3+CD4+CD25+ regulatory T cells induced by IL-2 and TGF-beta are resistant to Th17 conversion by IL-6. J. Immunol. 180(11), 7112–7116 (2008).
  • Tran DQ, Andersson J, Hardwick D, Bebris L, Illei GG, Shevach EM. Selective expression of latency-associated peptide (LAP) and IL-1 receptor Type I/II (CD121a/CD121b) on activated human FOXP3+ regulatory T cells allows for their purification from expansion cultures. Blood 113(21), 5125–5133 (2009).
  • Beyer M, Kochanek M, Darabi K et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 106(6), 2018–2025 (2005).
  • Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. CD4+CD25high regulatory cells in human peripheral blood. J. Immunol. 167(3), 1245–1253 (2001).
  • Mcmurchy AN, Bushell A, Levings MK, Wood KJ. Moving to tolerance: clinical application of T regulatory cells. Semin. immunol. 23(4), 304–313 (2011).
  • Khattar M, Chen W, Stepkowski SM. Expanding and converting regulatory T cells: a horizon for immunotherapy. Arch. Immunol. Ther. Exp. 57(3), 199–204 (2009).
  • Godfrey WR, Ge YG, Spoden DJ et al. In vitro-expanded human CD4+CD25+ T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures. Blood 104(2), 453–461 (2004).
  • Selvaraj RK, Geiger TL. A kinetic and dynamic analysis of Foxp3 induced in T cells by TGF-beta. J. Immunol. 179(2), 11 p following 1390 (2007).
  • Guo Z, Khattar M, Schroder PM et al. A dynamic dual role of IL-2 signaling in the two-step differentiation process of adaptive regulatory T Cells. J. Immunol. 190(7), 3153–3162 (2013).
  • Apostolou I, Sarukhan A, Klein L, Von Boehmer H. Origin of regulatory T cells with known specificity for antigen. Nat. Immunol. 3(8), 756–763 (2002).
  • Apostolou I, Von Boehmer H. In vivo instruction of suppressor commitment in naive T cells. J. Exp. Med. 199(10), 1401–1408 (2004).
  • Daniel C, Wennhold K, Kim HJ, Von Boehmer H. Enhancement of antigen-specific Treg vaccination in vivo. Proc. Nat Acad Sci US 107(37), 16246–16251 (2010).
  • Wolf D, Schreiber TH, Tryphonopoulos P et al. Tregs expanded in vivo by TNFRSF25 agonists promote cardiac allograft survival. Transplantation 94(6), 569–574 (2012).
  • Boyman O, Kovar M, Rubinstein MP, Surh CD, Sprent J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 311(5769), 1924–1927 (2006).
  • Vokaer B, Charbonnier LM, Lemaitre PH, Le Moine A. Impact of interleukin-2-expanded regulatory T cells in various allogeneic combinations on mouse skin graft survival. Transplant Proc. 44(9), 2840–2844 (2012).
  • Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 107(6), 2409–2414 (2006).
  • Koreth J, Matsuoka K, Kim HT et al. Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease. N Engl J Med 365(22), 2055–2066 (2011).
  • Hunig T. The storm has cleared: lessons from the CD28 superagonist TGN1412 trial. Nat. Rev. Immunol. 12(5), 317–318 (2012).
  • Sakaguchi S, Vignali DA, Rudensky AY, Niec RE, Waldmann H. The plasticity and stability of regulatory T cells. Nat. Rev. Immunol. 13(6), 461–467 (2013).
  • Williams LM, Rudensky AY. Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat. Immunol. 8(3), 277–284 (2007).
  • Tsuji M, Komatsu N, Kawamoto S et al. Preferential generation of follicular B helper T cells from Foxp3+ T cells in gut Peyer's patches. Science 323(5920), 1488–1492 (2009).
  • Duarte JH, Zelenay S, Bergman ML, Martins AC, Demengeot J. Natural Treg cells spontaneously differentiate into pathogenic helper cells in lymphopenic conditions. Eur. J. Immunol. 39(4), 948–955 (2009).
  • Komatsu N, Mariotti-Ferrandiz ME, Wang Y, Malissen B, Waldmann H, Hori S. Heterogeneity of natural Foxp3+ T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity. Proc. Natl Acad. Sci. USA 106(6), 1903–1908 (2009).
  • Floess S, Freyer J, Siewert C et al. Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol. 5(2), e38 (2007).
  • Polansky JK, Kretschmer K, Freyer J et al. DNA methylation controls Foxp3 gene expression. Eur. J. Immunol. 38(6), 1654–1663 (2008).
  • Rubtsov YP, Niec RE, Josefowicz S et al. Stability of the regulatory T cell lineage in vivo. Science 329(5999), 1667–1671 (2010).
  • Zhou X, Bailey-Bucktrout SL, Jeker LT et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat. Immunol. 10(9), 1000–1007 (2009).
  • Mcclymont SA, Putnam AL, Lee MR et al. Plasticity of human regulatory T cells in healthy subjects and patients with Type 1 diabetes. J. Immunol. 186(7), 3918–3926 (2011).

Websites

  • European Commission. ONE Study. www.onestudy.org (Acessed 4 August 2013)
  • Geissler E; University of Regensburg and European Commission. Reference Group Trial for The ONE Study. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US) 2000. http://clinicaltrials.gov/show/NCT01656135 (Acessed 1 August 2013)
  • Gitelman S, Bluestone J; University of California, San Francisco, Juvenile Diabetes Research Foundation, and National Institute of Allergy and Infectious Diseases. T1DM Immunotherapy Using CD4+CD127lo/-CD25+ Polyclonal Tregs. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US) 2000. http://clinicaltrials.gov/show/NCT01210664 (Acessed 1 August 2013)
  • Pidala J; H Lee Moffitt Cancer Center and Research Institute. Ex-vivo Expanded Donor Regulatory T Cells for Prevention of Acute Graft-versus-host Disease. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US) 2000. http://clinicaltrials.gov/show/NCT01795573 (Accessed 1 August 2013)
  • Johnston L; Stanford University and National Institutes of Health. Phase I Infused Donor T Regulatory Cells in Steroid-Dependent/Refractory Chronic GVHD. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US) 2000 http://clinicaltrials.gov/show/NCT01911039 (Accessed 1 August 2013)
  • Baron F; University Hospital of Liege. Donor Regulatory T Cells Infusion in Patients with Chronic Graft-versus-host Disease (GVHD). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US) 2000. http://clinicaltrials.gov/show/NCT01903473 (Accessed 1 August 2013)
  • Laport G; Stanford University and Doris Duke Charitable Foundation. Haploidentical Allogeneic Transplant w/Post Transplant Infusion of Regulatory T-cells (BMT Protocol 204). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US) 2000. http://clinicaltrials.gov/show/NCT01050764 (Accessed 1 August 2013)
  • Bykovskaia SN, Kaabak MM; The Russian State Medical University and Russian Academy of Medical Sciences. Treatment of Children with Kidney Transplants by Injection of CD4+CD25+FoxP3+ T Cells to Prevent Organ Rejection. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US) 2000. http://clinicaltrials.gov/show/NCT01446484 (Acessed 01 August 2013)
  • Lu L, Blazar B; Nanjing Medical University and University of Minnesota Clinical and Translational Science Institute. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US) 2000. http://clinicaltrials.gov/show/NCT01624077 (Acessed 1 August 2013)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.